Startseite>>Signaling Pathways>> Neuroscience>>Somatostatin-28 (1-14) (human, mouse, rat, porcine, bovine, ovine) (trifluoroacetate salt)

Somatostatin-28 (1-14) (human, mouse, rat, porcine, bovine, ovine) (trifluoroacetate salt)

Katalog-Nr.GC49483

An N-terminal fragment of somatostatin-28

Products are for research use only. Not for human use. We do not sell to patients.

Somatostatin-28 (1-14) (human, mouse, rat, porcine, bovine, ovine) (trifluoroacetate salt) Chemische Struktur

Cas No.: N/A

Größe Preis Lagerbestand Menge
1 mg
250,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28 .1 It has been used to produce antibodies selective for somatostatin-28 that do not bind to the C-terminal fragment somatostatin-14 .2

1.He, H.T., Johnson, K., Thermos, K., et al.Purification of a putative brain somatostatin receptorProc. Natl. Acad. Sci. U.S.A.86(5)1480-1484(1989) 2.Zeggari, M., Esteve, J.P., Rauly, I., et al.Co-purification of a protein tyrosine phosphatase with activated somatostatin receptors from rat pancreatic acinar membranesBiochem. J.303(Pt 2)441-448(1994)

Bewertungen

Review for Somatostatin-28 (1-14) (human, mouse, rat, porcine, bovine, ovine) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Somatostatin-28 (1-14) (human, mouse, rat, porcine, bovine, ovine) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.